Regulation of biosimilar medicines and current perspectives on interchangeability and policy
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Regulation of biosimilar medicines and current perspectives on interchangeability and policy
Authors
Keywords
Regulation, Biosimilar, Policy, Interchangeability, Switching, Substitution
Journal
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Nature America, Inc
Online
2018-09-06
DOI
10.1007/s00228-018-2542-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Biosimilarity and Interchangeability: Principles and Evidence: A Systematic Review
- (2018) Ross A. McKinnon et al. BIODRUGS
- Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches
- (2018) A. Blauvelt et al. BRITISH JOURNAL OF DERMATOLOGY
- Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes
- (2018) Hillel P. Cohen et al. DRUGS
- The nocebo effect challenges the non-medical infliximab switch in practice
- (2018) N. W. Boone et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Interchangeability of biosimilar and biological reference product: updated regulatory positions and pre- and post-marketing evidence
- (2017) Gianluca Trifirò et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Is there a reason for concern or is it just hype? – A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars
- (2017) András Inotai et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial
- (2017) Kristin K Jørgensen et al. LANCET
- Strengths, weaknesses and future challenges of biosimilars’ development. An opinion on how to improve the knowledge and use of biosimilars in clinical practice
- (2017) Cristina Scavone et al. PHARMACOLOGICAL RESEARCH
- Assessing awareness and attitudes of healthcare professionals on the use of biosimilar medicines: A survey of physicians and pharmacists in Ireland
- (2017) Joan O'Callaghan et al. REGULATORY TOXICOLOGY AND PHARMACOLOGY
- Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open-Label Transition From Reference Infliximab to Biosimilar Infliximab
- (2017) Lieke Tweehuysen et al. Arthritis & Rheumatology
- Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians
- (2016) Hillel Cohen et al. ADVANCES IN THERAPY
- Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study
- (2016) Won Park et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study
- (2016) Dae Hyun Yoo et al. ANNALS OF THE RHEUMATIC DISEASES
- Switching to biosimilar infliximab (CT-P13): Evidence of clinical safety, effectiveness and impact on public health
- (2016) Jürgen Braun et al. BIOLOGICALS
- The design of clinical trials to support the switching and alternation of biosimilars
- (2016) Freddy Faccin et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease—An Update
- (2016) Silvio Danese et al. Journal of Crohns & Colitis
- Postmarket policy considerations for biosimilar oncology drugs
- (2016) Matthew J Renwick et al. LANCET ONCOLOGY
- Attitudes towards subsequent entry biologics/biosimilars: A survey of Canadian rheumatologists
- (2015) David Grabowski et al. CLINICAL RHEUMATOLOGY
- Key considerations in the preclinical development of biosimilars
- (2015) Lynne A. Bui et al. DRUG DISCOVERY TODAY
- Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data
- (2015) Elena Nikiphorou et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Biosimilars in rheumatology: current perspectives and lessons learnt
- (2015) Thomas Dörner et al. Nature Reviews Rheumatology
- Biosimilarity Versus Manufacturing Change: Two Distinct Concepts
- (2015) Paul Declerck et al. PHARMACEUTICAL RESEARCH
- The use of biosimilars in immune-mediated disease: A joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper
- (2014) Gionata Fiorino et al. AUTOIMMUNITY REVIEWS
- Biosimilars: the science of extrapolation
- (2014) M. Weise et al. BLOOD
- Beliefs, perceptions and behaviours of GPs towards generic medicines
- (2014) S. S. Dunne et al. FAMILY PRACTICE
- Biosimilars entering the clinic without animal studies
- (2014) Leon AGJM van Aerts et al. mAbs
- Biosimilars in rheumatology: the wind of change
- (2013) Christian K Schneider ANNALS OF THE RHEUMATIC DISEASES
- The nocebo effect: patient expectations and medication side effects
- (2013) Kate Faasse et al. POSTGRADUATE MEDICAL JOURNAL
- Joint position statement by "Sociedad Española de Patología Digestiva" (Spanish Society of Gastroenterology) and "Sociedad Española de Farmacología" (Spanish Society of Pharmacology) on biosimilar therapy for inflammatory bowel disease
- (2013) Federico Argüelles-Arias et al. REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS
- Biosimilars: what clinicians should know
- (2012) M. Weise et al. BLOOD
- The safety of switching between therapeutic proteins
- (2012) Hans C Ebbers et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- The economic pressures for biosimilar drug use in cancer medicine
- (2012) Paul Cornes Targeted Oncology
- Biosimilars of Biological Drug Therapies
- (2011) George Dranitsaris et al. DRUGS
- Worldwide experience with biosimilar development
- (2011) Mark McCamish et al. mAbs
- The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose and How to Predict Response?
- (2010) Geert R D'Haens et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Switching biologics for psoriasis
- (2010) Anthony D. Ormerod BRITISH JOURNAL OF DERMATOLOGY
- Assessing the bioequivalence of biosimilars
- (2009) H. Schellekens DRUG DISCOVERY TODAY
- Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix®30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE™ observational study
- (2009) P. Valensi et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now